Akum's Breakthrough Tablet Brings Relief for Morning Sickness

India Pharma Outlook Team | Tuesday, 06 May 2025

 Akum's Breakthrough Tablet Brings Relief for Morning Sickness

Akums Drugs & Pharmaceuticals Ltd., a leading Indian pharmaceutical company, just got a patent for a new tablet that’s a game-changer for pregnant women struggling with nausea and vomiting. This exciting invention is here to make pregnancy a little easier for moms-to-be.

Morning sickness hits up to 80% of pregnant women, making it tough to eat, work, or just feel okay. For most, it fades after a few months, but about 20% deal with it their whole pregnancy. Akums’ new tablet is designed to help. It’s got a clever “tablet-in-tablet” setup: the outer part kicks in fast to stop nausea, and the inner part keeps working to keep it away longer. This means fewer pills to take, which is a big relief when you’re already juggling so much.

The tablet was carefully tested and approved by India’s drug authorities, so you know it’s safe and works well. While the study details aren’t shared publicly, the results show it’s helping women feel better and manage their symptoms.

Sanjeev Jain, Akums’ Managing Director, couldn’t be prouder. “Our ‘tablet-in-tablet’ technology reflects our commitment to addressing real-world health challenges. By improving access to safe, effective solutions for NVP, we’re supporting expectant mothers during a vital phase of life.”

Akums is a powerhouse in making medicines, with over 4,100 products out there and 220 more in the pipeline. They’ve got 12 modern factories and four research labs with over 400 scientists dreaming up new ways to improve health. This tablet is just one example of how they’re tackling real problems with smart solutions.

For pregnant women, this new tablet is a breath of fresh air, offering a simple way to handle morning sickness. As Akums keeps growing and reaching more people worldwide, they’re staying true to their mission of creating medicines that make life better for everyone.

© 2025 India Pharma Outlook. All Rights Reserved.